Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
1995 1
1996 1
2002 4
2006 1
2008 3
2009 1
2014 1
2015 1
2016 2
2017 1
2018 3
2020 1
2021 2
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Marzolini C, et al. Among authors: pozniak a. Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7. Clin Pharmacol Ther. 2022. PMID: 35567754 Free PMC article. Review.
Second-Line Switch to Dolutegravir for Treatment of HIV Infection.
Ombajo LA, Penner J, Nkuranga J, Mecha J, Mburu M, Odhiambo C, Ndinya F, Aksam R, Njenga R, Wahome S, Muiruri P, Eshiwani S, Kimani M, Ngugi C, Pozniak A. Ombajo LA, et al. Among authors: pozniak a. N Engl J Med. 2023 Jun 22;388(25):2349-2359. doi: 10.1056/NEJMoa2210005. N Engl J Med. 2023. PMID: 37342923 Clinical Trial.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
Saumoy M, Sánchez-Quesada JL, Assoumou L, Gatell JM, González-Cordón A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masiá M, Ordónez-Llanos J, Pozniak A, Martínez E, Podzamczer D. Saumoy M, et al. Among authors: pozniak a. J Antimicrob Chemother. 2022 Jun 29;77(7):1980-1988. doi: 10.1093/jac/dkac117. J Antimicrob Chemother. 2022. PMID: 35411401 Clinical Trial.
In the dolutegravir arm, after 48 weeks, we observed: (1) an increase in LDL size [median 1.65 A (IQR -0.60 to 4.20); P = 0.007], correlated with the decrease in triglyceride concentration [Spearman correlation = -0.352 (P = 0.001)], with a corresponding decrease of subjects with …
In the dolutegravir arm, after 48 weeks, we observed: (1) an increase in LDL size [median 1.65 A (IQR -0.60 to 4.20); P = 0.007], correlated …
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19.
Arber N, Shah PL, Assoumou L, Rokx C, De Castro N, Bakhai A, Soriano Viladomiu A, Mateu L, Lumbreras C, Estrada V, Curran A, Sellier PO, Duffy A, Fletcher C, Mozaffari E, Haubrich R, Hodgkins P, Pozniak A, Raffi F. Arber N, et al. Among authors: pozniak a. Infect Dis Now. 2023 Oct;53(7):104760. doi: 10.1016/j.idnow.2023.104760. Epub 2023 Jul 14. Infect Dis Now. 2023. PMID: 37454762
Patients were categorised by baseline disease severity: no supplemental oxygen (NSO); low flow oxygen 6 litres (l)/minute (LFO); high flow oxygen > 6 l/minute (HFO). RESULTS: Four hundred and forty-eight (448) patients (72 [16.1%] HFO; 295 [65.8%] LFO; 81 (18.1%] …
Patients were categorised by baseline disease severity: no supplemental oxygen (NSO); low flow oxygen 6 litres (l)/minute (LFO); high …
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.
Lazarus JV, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, Bekker LG, Bhagani S, Brown D, Brown G, Buchbinder S, Caceres C, Cahn PE, Carrieri P, Caswell G, Cooke GS, Monforte AD, Dedes N, Del Amo J, Elliott R, El-Sadr WM, Fuster-Ruiz de Apodaca MJ, Guaraldi G, Hallett T, Harding R, Hellard M, Jaffar S, Kall M, Klein M, Lewin SR, Mayer K, Pérez-Molina JA, Moraa D, Naniche D, Nash D, Noori T, Pozniak A, Rajasuriar R, Reiss P, Rizk N, Rockstroh J, Romero D, Sabin C, Serwadda D, Waters L. Lazarus JV, et al. Among authors: pozniak a. Nat Commun. 2021 Jul 16;12(1):4450. doi: 10.1038/s41467-021-24673-w. Nat Commun. 2021. PMID: 34272399 Free PMC article. Review.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Among authors: pozniak a. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.
Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C. Bekker LG, et al. Among authors: pozniak a. Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Lancet. 2018. PMID: 30032975 Free PMC article. Review. No abstract available.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Sempere A, Assoumou L, González-Cordón A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martínez E; NEAT 022 Study Group. Sempere A, et al. Among authors: pozniak a. Clin Infect Dis. 2023 Oct 5;77(7):991-1009. doi: 10.1093/cid/ciad297. Clin Infect Dis. 2023. PMID: 37207617
Lessons for the HIV response from structural innovations catalysed by COVID-19.
Isbell M, Bekker LG, Grinsztejn B, Kates J, Kamarulzaman A, Lewin SR, Ngure K, Phanuphak N, Pozniak A, Grimsrud A. Isbell M, et al. Among authors: pozniak a. BMJ Glob Health. 2022 Nov;7(11):e010854. doi: 10.1136/bmjgh-2022-010854. BMJ Glob Health. 2022. PMID: 36446447 Free PMC article. No abstract available.
33 results